The percentage of patients with severe QOL impairment ( 2 SD below community norm ) at week 12 was significantly lower for desvenlafaxine ( 46 % ) vs placebo ( 62 % ; P = 0.0024 ; baseline : 95 % and 94 % , respectively ) .